SETD2 and nonpapillary renal cell carcinoma: The purpose of this phase II study (NCT03284385) was to evaluate the efficacy and safety of adavosertib monotherapy in patients with SETD2-altered ccRCC and other locally advanced or metastatic solid tumor malignancies.